Statin Muscle Pain May Be Linked to a Genetic Mutation, Mouse Study Finds

A genetic difference may help explain why some people develop muscle pain while taking statins, according to a preliminary 2025 study in the Journal of Clinical Investigation. The research points to altered calcium release in muscle cells, but it’s been tested only in mice, so it doesn’t establish why patients experience statin-associated muscle symptoms (SAMS). The result is a possible mechanism, not an answer about what causes symptoms in any particular person.

A possible link between genes and muscle symptoms

Researchers compared genetically unmodified mice with mice carrying a mutation that affects skeletal muscle receptors. After both groups received simvastatin, the mice with the mutation were more prone to symptoms resembling SAMS. The mutation appeared to change how calcium was released, allowing more calcium to enter muscle cells and potentially triggering pain or discomfort. That sequence gives researchers something specific to test: whether a change in calcium handling can connect a genetic difference to muscle symptoms during statin exposure.

The finding offers a mechanism to investigate, but it doesn’t show that the mutation explains most reported cases. Statins themselves may not be the sole explanation for muscle symptoms; a person’s genetic makeup could influence how their muscles respond to the medication. Similar medication side effects can have more than one contributing factor, so a single pathway may account for only some experiences. Whether this process occurs in humans remains unknown.

That uncertainty matters because muscle aches and cramps are among the most frequently reported reasons patients stop taking statins. As many as 10% of people prescribed the drugs develop muscle symptoms, though many take them without difficulty. The distinction matters in practice: symptoms can be real and disruptive even while the precise cause remains unclear.

Why the finding matters to clinicians

Statins remain an effective way to lower LDL cholesterol and reduce the risk of heart attack and stroke. Catherine Benziger, M.D., a member of the American College of Cardiology Prevention of Cardiovascular Diseases Council, says symptoms vary: some patients have mild discomfort and can continue treatment, while others experience symptoms severe enough to stop. That range makes it difficult to treat every complaint as the same clinical problem. A clearer biological explanation could help clinicians ask better questions, though this mouse study doesn’t yet provide a way to predict who will develop symptoms.

Cheng-Han Chen, M.D., an interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center, says a clearer account of the underlying cause could help clinicians identify patients more likely to experience muscle symptoms and find ways to limit them. Benziger also says a defined mechanism could make it easier to explain symptoms to patients. That explanation has practical value: uncertainty can leave patients unsure whether to keep taking a medicine that helps lower cardiovascular risk. The numbers here are underwhelming as a basis for immediate clinical decisions, since the proposed link hasn’t been confirmed in people.

The study raises a further possibility: a drug aimed at the mutation might eventually prevent symptoms, Chen says. That could help some patients remain on statins. This is more significant than it looks if the mechanism proves relevant in humans, because it would point toward addressing a specific muscle response rather than abandoning cholesterol treatment altogether. For now, that’s a research direction, not an available treatment.

What patients should do about symptoms

People taking statins should discuss new muscle symptoms with their doctor before making changes to treatment. Benziger says that in her practice, she may advise a patient with muscle side effects to pause the statin for five to seven days and see whether symptoms resolve, then restart it. If symptoms return, she suggests discussing a different statin or a lower dose with the clinician. That approach is an example of her practice, not a plan every patient should follow without medical guidance.

If you’re working through muscle symptoms, the study doesn’t tell you whether your medication is the cause or whether you carry the mutation. It also doesn’t change the need to weigh symptoms against the reason the statin was prescribed. Here’s the thing: a careful conversation with the prescribing clinician can help sort out treatment options while keeping cardiovascular risk in view.

Some patients may not tolerate statins even after adjustments. In that case, Chen and Benziger recommend talking with a doctor about other cholesterol-lowering medicines, including PCSK9 inhibitors or bempedoic acid. Benziger stresses that cholesterol management remains important, particularly for people with diabetes, kidney disease, prior heart disease, an elevated coronary artery calcium score, or other risk factors. The appropriate option depends on the patient’s circumstances and should be discussed with a clinician.

Human studies are the next step

The key limitation is straightforward: researchers observed the proposed mechanism in mice. Chen says further work must determine whether it applies to people. Human research would need to establish whether the same calcium changes occur in patients with symptoms and whether the genetic difference helps explain who is affected. Until then, the study can guide questions for research, but it can’t support a diagnostic test or treatment choice.

If human research confirms the link, the findings could guide future approaches to reducing muscle symptoms or developing treatments that avoid this limitation. And yet, even confirmation of one mechanism wouldn’t necessarily account for every patient’s experience. The value would be in clarifying one possible pathway and testing whether it can lead to more tailored care.

What the study means next

For now, the study gives researchers a testable explanation for a common barrier to statin use. Its reach is limited by the gap between a controlled mouse experiment and the varied experiences of people taking medication. That gap is where the next work has to happen.

For patients, the practical takeaway is to report muscle symptoms and work with a clinician on treatment adjustments or alternatives. A possible genetic explanation may eventually sharpen those discussions. Not yet.